What is the purpose of this study?

The aims of this analysis were the evaluation of (1) the rate of conversion from MRD-positivity (MRD-pos) to MRD-negativity (MRD-neg) with MFC and NGS during maintenance and (2) the impact on progression-free survival (PFS) and overall survival (OS) of MRD-neg with both techniques in different subgroups including different treatment arms.

In this video:

Dr. Stefania Oliva gives a report on the results of the FORTE trial on MRD via multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) techniques. MRD was evaluated by these two techniques and the best technique between these two was evaluated.

Results:

The outcomes of patients who were MRD-NEG by MFC and NGS at 10^-5 were similar, as well as those of patients with 1-year sustained MRD-NEG by MFC and NGS. 

Conclusion:

The final outcome of MRD negative patients is superimposable regardless of treament. High degree of clinical concordance between MFC and NGS MRD.

ASH 2020: Abstract 491

STEFANIA OLIVA, MD, PhD

Dr. Stefania Oliva isa member of the Myeloma Unit, Division of Hematology, University of Torino, Turin University Hospital Azienda Ospedaliero‐Universitaria Città della Salute e della Scienza di Torino.